New Zealand markets open in 6 hours

EQRx, Inc. (EQRX)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
4.6800+0.1000 (+2.18%)
As of 12:00PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close4.5800
Open4.4600
Bid4.6100 x 1400
Ask4.6200 x 1100
Day's range4.4600 - 4.6800
52-week range2.6300 - 10.4900
Volume503,139
Avg. volume2,006,156
Market cap2.283B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-0.1460
Earnings date13 May 2022
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est6.80
  • GlobeNewswire

    EQRx Announces Acceptance of Marketing Authorization Application by the UK's Medicines and Healthcare Products Regulatory Agency for Aumolertinib in EGFR-Mutated Non-small Cell Lung Cancer

    Marketing authorization application is EQRx’s first submission to a regulatory agencyApplication is based on data from pivotal Phase 3 AENEAS trial in the first-line treatment of EGFR-mutated non-small cell lung cancer CAMBRIDGE, Mass., June 14, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices, today announced that the United Kingdom (U.K.)’s Medicines and Hea

  • GlobeNewswire

    EQRx to Participate at Upcoming Investor Conferences

    CAMBRIDGE, Mass., May 31, 2022 (GLOBE NEWSWIRE) -- EQRx, Inc. (Nasdaq: EQRX), a new type of pharmaceutical company committed to developing and delivering innovative medicines to patients at radically lower prices, today announced that management will participate in the following investor conferences in June: Jefferies Global Healthcare ConferenceFireside Chat: Thursday, June 9, 2022, 11:30 a.m. PT / 2:30 p.m. ET Goldman Sachs 43rd Annual Global Healthcare ConferenceFireside Chat: Tuesday, June 1

  • GlobeNewswire

    EQRx Announces New Data for Lead Oncology Programs in Non-small Cell Lung Cancer and Rare Form of Non-Hodgkin Lymphoma at ASCO 2022

    In a Phase 3 clinical trial, the addition of sugemalimab to chemotherapy improved median overall survival by 8.5 months versus placebo plus chemotherapy in people with previously untreated Stage IV non-small cell lung cancer (NSCLC)In a Phase 2 trial, sugemalimab treatment resulted in durable responses in people with relapsed or refractory extranodal natural killer/T-cell lymphoma, with approximately half of patients achieving a response and approximately one third achieving a complete responseI